AUSTRALIA'S #1 ONLINE CPD EDUCATION PLATFORM

Join Dr Allan Shell, Prof James Vickers and Prof Dimity Pond as we discuss the latest developments in dementia care.
This year we celebrate the centenary of the modern era of diabetology which began with the discovery of insulin in 1921.

This clinical audit aims to improve the management of patients with iron deficiency following oral or IV iron supplementation.

This module aims to educate GPs on the late effects of polio and how to identify and support affected patients.

This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.

This education explores how to identify patients at elevated risk of cancer due to Lynch syndrome, and provides an overview of how Family Cancer Clinics can assist these patients through genetic testing and...

Rethinking first injectable therapies in type 2 diabetes: A practical approach

This accredited learning module explores how to initiate injectable therapy in a patient with type 2 diabetes who remains above their glycaemic target despite taking dual or triple oral therapy. The activity works through 3 in-depth case-studies: a patient with uncomplicated T2D, a patient with ASCVD risk, and a patient with established ASCVD.

What's polio got to do with general practice in Australia in 2021?

Late effects of polio include post-polio syndrome and symptoms such as residual weakness, musculoskeletal imbalance, growth retardation or skeletal deformities in affected limbs, respiratory insufficiency and cold intolerance due to circulatory disturbances. Many patients living with the late effects of polio are unaware that their current presenting symptoms could be related to their initial polio infection. This module aims to educate GPs on the late effects of polio and how to identify and support affected patients.

T2D injectables: 1. Intensifying to first injectable therapy in uncomplicated type 2 diabetes

This education module focuses on a case study of an uncomplicated patient with type 2 diabetes, and the process of intensifying to first injectable therapy. Expert video commentary throughout the module helps step the participant through the decision cycle from the ADA/EASD consensus guidelines for T2D. This module also includes Australian recommendations for patients fasting during Ramadan.

T2D injectables: 2. Intensifying to first injectable therapy in patients with ASCVD risk

In this education module, the participant will work through a case study of a type 2 diabetes patient with ASCVD risk factors. The case study uses the decision cycle from the ADA/EASD consensus guidelines for T2D, and features expert video commentary. The module also discusses patient-related concerns leading to clinical inertia, including useful management decisions when faced with this issue.

Pages